Hara T, et al. - Researchers have shown previously in phase 2 studies that the combination of rituximab (R), tetrahydropyranyl adriamycin (THP), cyclophosphamide (CPA), vincristine (VCR), and prednisolone (PSL), also known as R-THP-COP, demonstrates efficacy and safety in the treatment of diffuse large B cell lymphoma (DLBCL). This noninferiority phase 3 trial was performed to compare the efficacy and safety of the R-THP-COP vs standard R-CHOP regimen (consisting of R, CPA, DOX, VCR, and PSL) among patients younger than 70 years of age with previously untreated DLBCL. They found that when compared with R-CHOP, R-THP-COP had a noninferior clinical response and an acceptable safety profile, and therefore may be an alternative to R-CHOP.